ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GNS Genus Plc

1,860.00
-8.00 (-0.43%)
14 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genus Plc LSE:GNS London Ordinary Share GB0002074580 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -8.00 -0.43% 1,860.00 1,860.00 1,872.00 1,890.00 1,830.00 1,830.00 829,710 16:35:25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 689.7M 33.3M 0.5043 37.08 1.23B

Genus PLC Non-Executive Director Retirement (4303V)

02/11/2017 2:01pm

UK Regulatory


Genus (LSE:GNS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Genus Charts.

TIDMGNS

RNS Number : 4303V

Genus PLC

02 November 2017

FOR IMMEDIATE RELEASE

2 November 2017

Genus plc

Non-Executive Director Retirement

Genus plc (LSE: GNS), a leading global animal genetics company, announces that Duncan Maskell, Non-Executive Director, has informed the Company of his intention to step down from the Genus Board, effective from the 2018 Annual General Meeting. Professor Maskell has served as a Non-Executive Director and advisor to the Company's Research and Development Portfolio Management Team for almost four years and has announced his intention to move to Melbourne, Australia following his appointment as Vice-Chancellor of the University of Melbourne.

Commenting on Professor Maskell's departure, Bob Lawson, Chairman of Genus, said:

"I'm delighted that Duncan is able to continue his work as a Non-Executive Director over the course of the next year, while he settles into his new role at the University of Melbourne. Over the last four years, Duncan has provided the Company with significant scientific expertise, guidance and insight as we progress our innovative platforms in genomics, gene editing and biosystems engineering. We look forward to continuing to work with Duncan over the next year, and wish him the very best in his new role."

For further information please contact:

Genus:

   Bob Lawson, Chairman                                                  Tel: +44 (0)1256 345970 

Karim Bitar, Chief Executive

Buchanan:

   Charles Ryland / Vicky Hayns                                       Tel: +44 (0)207 466 5000 

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAUGGRAGUPMGWP

(END) Dow Jones Newswires

November 02, 2017 10:01 ET (14:01 GMT)

1 Year Genus Chart

1 Year Genus Chart

1 Month Genus Chart

1 Month Genus Chart

Your Recent History

Delayed Upgrade Clock